Hong-Van Tieu

Hong-Van Tieu

Auto-generated profile, based on publicly available information

Hong-Van Tieu

New York Blood Center

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
KPK. Rachael Parks
K. Rachael Parks
ZMZoe Moodie
Zoe Moodie
MAMary A. Allen
Mary A. Allen
CYCatherine Yen
Catherine Yen
BFBriana D. Furch
Briana D. Furch
MMM. Juliana McElrath
M. Juliana McElrath
MRNA technology might accelerate development of an urgently needed preventive human immunodeficiency virus (HIV) vaccine. We evaluated the safety and immunogenicity of three mRNA-encoded envelope trimers, including two doses of soluble and membrane-anchored forms, in a randomized, open-label, phase 1 clinical trial. Vaccines were generally well tolerated, although 6.5% (7 of 108) of participants developed urticaria, a higher proportion than seen with other mRNA vaccines. mRNA-encoded trimers induced strong envelope-specific B and T cell responses. Immunization with membrane-anchored trimers, intended to obscure epitopes at the trimer base targeted by nonneutralizing antibodies, reduced the frequency of base-binding serum antibodies in comparison with soluble trimers. Three immunizations elicited autologous tier 2 serum neutralizing antibodies in 80% of vaccinees receiving the membrane-anchored trimers, in contrast to only 4% receiving the soluble trimer. Thus, with demonstration of more favorable safety, mRNA-encoded membrane-anchored HIV envelope trimers represent a promising platform for HIV vaccine clinical development.

4 February 2021 in Culture, Health & Sexuality
Verified
Journal Article
Closed access
GJGabriella Y. Jackson
Gabriella Y. Jackson
CDCaroline K. Darlington
Caroline K. Darlington
HTHong Van Tieu
Hong Van Tieu
BBBridgette M. Brawner
Bridgette M. Brawner
DFDalmacio Flores
Dalmacio Flores
ATAnne M. Teitelman
Anne M. Teitelman
Since the beginning of the HIV epidemic in the USA, effective interventions to reduce HIV risk among cisgender women have been lacking. Although oral HIV pre-exposure prophylaxis (PrEP) is effective in pharmacologically preventing HIV infection, there is a gap between the recommended use of PrEP and PrEP uptake among eligible women. This study aimed to identify the role of patient-provider communication in PrEP decision-making among women considering PrEP. Semi-structured in-depth interviews were conducted with 41 PrEP-eligible women in Philadelphia and New York City. A thematic analysis of the responses was conducted, and a conceptual model developed and confirmed as analysis continued. Of the women interviewed, 53.6% were African American and 29.3% were Latina. Women noted that having a trusting relationship with their health care provider, receiving a tailored recommendation for PrEP based upon their specific needs and using their health care provider as support were crucial facilitators of PrEP decision-making. Lack of provider knowledge about PrEP, perceived health care provider stigma about their drug use and sexual activity, and lack of care continuity were all identified as barriers to effective communication. Study findings can inform future interventions to enhance patient-provider communication about PrEP and increase PrEP uptake among women.

1 November 2018 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
SHSabina Hirshfield
Sabina Hirshfield
RTRichard A Teran
Richard A Teran
MJMartin J Downing Jr
Martin J Downing Jr
MCMary Ann Chiasson
Mary Ann Chiasson
HTHong-Van Tieu
Hong-Van Tieu
CGCharlotte A Gaydos
Charlotte A Gaydos
A multidisciplinary journal that focuses on public health and technology, public health informatics, mass media campaigns, surveillance, and innovation in public health practice and research. Also dedicated to rapid open data sharing during epidemics.

15 September 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MSMagdalena E. Sobieszczyk
Magdalena E. Sobieszczyk
JMJill Maaske
Jill Maaske
AFAnn Regina Falsey
Ann Regina Falsey
SSStephanie Sproule
Stephanie Sproule
MRMerlin L. Robb
Merlin L. Robb
IHIan Hirsch
Ian Hirsch
Background. We report updated safety, efficacy, and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) from an ongoing phase 3 trial. Methods. Adults at increased risk of SARS-CoV-2 infection were randomized (2:1), stratified by age, to receive 2 doses of AZD1222 or placebo. The primary efficacy end point was confirmed SARS-CoV-2 reverse-transcriptase PCR–positive (RT-PCR–positive) symptomatic COVID-19 at 15 or more days after a second dose in baseline SARS-CoV-2–seronegative participants. The 21,634 and 10,816 participants were randomized to AZD1222 and placebo, respectively. Findings. Data cutoff for this analysis was July 30, 2021; median follow-up from second dose was 78 and 71 days for the double-blind period (censoring at unblinding or nonstudy COVID-19 vaccination) and 201 and 82 days for the period to nonstudy COVID-19 vaccination (regardless of unblinding) in the AZD1222 and placebo groups, respectively. For the primary efficacy end point in the double-blind period (141 and 184 events; incidence rates: 39.2 and 118.8 per 1,000 person years), vaccine efficacy was 67.0% (P < 0.001). In the period to nonstudy COVID-19 vaccination, incidence of events remained consistently low and stable through 6 months in the AZD1222 group; for the primary efficacy end point (328 and 219 events; incidence rates: 36.4, 108.4) and severe/critical disease (5 and 13 events; incidence rates: 0.6, 6.4), respective vaccine efficacy estimates were 65.1% and 92.1%. AZD1222 elicited humoral immune responses over time, with waning at day 180. No emergent safety issues were seen. Conclusion. AZD1222 is safe and well tolerated, demonstrating durable protection and immunogenicity with median follow-up (AZD1222 group) of 6 months. Trial registration. ClinicalTrials.gov NCT04516746. Funding. AstraZeneca; US government.

9 March 2021 in AIDS Care
Verified
Journal Article
Closed access
ATAnne M. Teitelman
Anne M. Teitelman
HTHong-Van Tieu
Hong-Van Tieu
DFDalmacio Flores
Dalmacio Flores
JBJacqueline Bannon
Jacqueline Bannon
BBBridgette M. Brawner
Bridgette M. Brawner
BKBeryl Koblin
Beryl Koblin
The underutilization of pre-exposure prophylaxis (PrEP) among cisgender women in the U.S. limits this population’s ability to reduce their risk for HIV infection, especially within the unique individual, social and structural systems they navigate. There is a need to identify the relevant multi-level barriers and facilitators to PrEP use among cisgender women to inform theory-guided efforts that address HIV disparities by race/ethnicity among cisgender women. Guided by the Integrated Behavioral Model and the Behavioral Model of Vulnerble Populations we conducted 41 interviews with PrEP eligible cisgender women in New York City and Philadelphia. Directed content analysis identified 11 modal behavioral beliefs crucial to PrEP uptake, including anticipated negative social consequences, 5 normative beliefs centered on available social supports, and 9 control beliefs such as anticipated barriers such as cost. Awareness and knowledge of PrEP as a biobehavioral HIV prevention method is limited for this sample. Through conventional content analysis we identified interpersonal and structural barriers to PrEP uptake including lack of partner support, transportation, mental health challenges, and challenges in accessing PrEP care. Potential solutions to structural barriers were enumerated along with implications for future intervention work and public health programming.